CD19 and non-Hodgkin lymphoma: This study aims to explore the efficacy and safety of ASMs implementation in two real-world cohorts adopting different (primary and pre-emptive) seizures prophylaxis strategies in non-Hodgkin lymphoma patients treated with anti-CD19 CAR T-cells.